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Background: Inappropriate drug use has been identified as one of the most important problems affecting the
quality of care in older people. Inappropriate drug use may increase the risk of the occurrence of ‘geriatric giants’
such as immobility, instability, incontinence and cognitive impairment. There are indications that clinical medication
reviews (CMR) can reduce inappropriate drug use. However, CMRs have not yet been implemented at a large scale
in primary care. An innovative medication review program in primary care will be developed which tackles the
most important obstacles for a large scale implementation of CMRs. The aim of this study is to assess whether this
CMR program is (cost-) effective compared with usual general practice care for older patients with geriatric
symptoms with regard to quality of life and geriatric symptoms.
Methods: A cluster randomised controlled trial will be performed in 20 Dutch general practices including 500
patients. Patients of 65 years and older are eligible if they newly present with pre-specified geriatric symptoms in
general practice and chronic use of at least one prescribed drug. GP practices will be stratified by practice size and
randomly allocated to control (n = 10) or intervention group (n = 10). The intervention consists of CMRs which will
be facilitated and prepared by an expert team consisting of a GP and a pharmacist. Primary outcome measures are
patient’s quality of life and the presence of self-reported geriatric symptoms during a follow-up period of 6 months.
Secondary outcomes are costs of healthcare utilisation, feasibility, number of drug related problems, medication
adherence and satisfaction with medication.
Discussion: This study is expected to add evidence on the (cost-) effectiveness of an optimally facilitated, prepared
and structured CMR in comparison with usual care in older patients who present a geriatric symptom to their GP.
The strength of this study is that it will be conducted in daily clinical practice. This improves the possibilities to
implement the CMRs in the primary care setting on a large scale.
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Inappropriate drug use has been identified as one of the
most important problems affecting the quality of care in
older people. Appropriate drug use and prescribing in
older people is difficult, because of the variability of age-
related changes in the metabolism, multimorbidity and
polypharmacy [1,2]. In addition, undertreatment of espe-
cially preventive medication as well as poor treatment
adherence are frequently occurring problems in older
people [3]. Because of changes in pharmacokinetics and
pharmacodynamics, older people are more prone to re-
duced effectiveness of drugs and they may be at higher
risk of adverse events and other drug related problems
(DRP) [4]. Several studies have shown associations be-
tween inappropriate drug use and clinical outcomes such
as hospital admissions, falling, adverse drug reactions
and functional decline [3,5-8].
Inappropriate drug use may increase the risk of the oc-
currence and persistence of geriatric problems [3,5,6,9-15].
The most common major impairments that appear in older
people, also referred to as “geriatric giants” are immobility,
instability, including falls and dizziness, incontinence and
cognitive impairment [16]. The atypical, silent, non-specific
disease presentation of a geriatric giant is a common type
of symptom presentation in the older adult and associ-
ated with limitations of activities of daily living (ADL)
[7]. The multi-factorial causes of geriatric giants often
include DRPs which can be prescriber-related (e.g. med-
ically non-indicated medication or inappropriate dosage),
but also patient-related, e.g. ineffectiveness of drugs, ad-
verse effects, lack of knowledge and usage of the drugs,
and non-adherence [6].
There are indications that clinical medication reviews
(CMR) can reduce inappropriate drug use in older
people. A CMR is ‘a structured, critical examination of
the patient’s medicines with the objective of reaching an
agreement with the patient about treatment, optimising
the impact of medicines, and minimising the number of
drug related problems’ [17]. It has been shown that spe-
cific subgroups can benefit from a CMR during or im-
mediately after hospital admissions [18,19]. In several
countries guidelines are developed for CMRs in older
and polypharmacy patients [17,20-22]. However, CMRs
have not yet been implemented at a large scale because
of several obstacles.
First, the evidence for the effectiveness of CMRs is not
very extensive and convincing. Several studies have
shown positive effects of CMRs on intermediate out-
comes such as the number of DRPs, medication adher-
ence and patient satisfaction with medication. However,
these effects are heterogeneous and so far, few effects
have been established on clinical outcome measures as
quality of life, hospital admissions or mortality [23-26].
This lack of evidence hinders the provision of financialincentives and motivation of healthcare professionals for
further implementation of CMRs.
Second, the best target group for CMRs may be unclear.
At present, patients in primary care are often selected
based the number of medications, the polypharmacy cri-
teria, which is a large group and not every polypharmacy
patient may need a CMR. The current study addresses the
appropriateness of medication use in patients who newly
present themselves with “geriatric giant” symptoms in
general practice. The patients will be selected irrespective
of the number of drugs used. Previous research has shown
that in many of these geriatric giants, suboptimal pharma-
cotherapy plays an important role in the occurrence and/
or persistence of the problems. Undertreatment in these
patients is just as often a problem as overtreatment [27].
The third obstacle of CMR implementation is its feasi-
bility. A CMR requires a considerable time investment
for each review varying from 15 to 60 minutes for a
physician and from 30 to 120 minutes for a pharmacist
[28]. The current Dutch guideline for polypharmacy in
older people recommends in addition to obtain the pa-
tient’s input preferably by a home visit and follows the
Systematic Tool to Reduce Inappropriate Prescribing
(STRIP) method, which includes at least two patient
contacts [20,29]. In addition, both lack of knowledge as
well as insufficient training of both the GPs as well as
the pharmacists hinder the implementation of CMRs. Fi-
nally the lack of comprehensive organisation of medical
data infrastructure and exchange between professionals
are hindering factors.
In this study an innovative CMR program (Opti-Med)
will be developed to tackle these obstacles in a primary
care setting. This Opti-Med study aims at providing scien-
tific evidence for the effectiveness on quality of life and
geriatric symptoms of an optimally facilitated, prepared
and structured CMR in comparison with usual care in
older patients presenting with a new geriatric giant to their
GP. The feasibility of implementing the program in the
daily routine of several GP practices will be evaluated.
Methods
The Opti-Med study protocol was approved by the Med-
ical Ethics Committee of the VU University Medical
Centre Amsterdam (reference 2011/408). For the de-
scription of the design of the Opti-Med intervention, the
Consolidated Standards of Reporting Trials (CONSORT)
statement with extension to cluster randomised trials is
followed [30].
Study design
A cluster randomised clinical trial will be performed in 20
general practices including 500 patients (see Figure 1). Al-
location of the intervention and control condition will be
carried out randomly at practice level. Eligible patients will
Figure 1 Study design of Opti-Med.
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of the patients listed in the intervention practices will be
reviewed. Patients listed in the control practices will re-
ceive usual care, with no systematic attention for their
medication. The effects of this intervention will be
assessed after a follow-up period of 6 months. The ration-
ale to use a cluster design at practice level is to prevent
contamination of structural attention to CMR activities
within the GP practice.
Setting
The study will be embedded in the Academic Network
of General Practices of the VU University Medical
Centre (ANH-VUmc) that consists of 20 GP practices in
Amsterdam, the Netherlands. Similar to almost all GPs
in the Netherlands, the GPs in this network use electronic
medical record systems in which all patients contact diag-
noses are coded using the International Classification of Pri-
mary Care first edition (ICPC-1) [31]. All practices employ
practice nurses who can assist with the implementation of
the intervention, have not yet systematically implemented
structured CMR and are therefore eligible for this trial.
This CMR program is tuned to the Dutch healthcare
setting where patients are listed with a general practiceand their GP is the first contact point for a patient with
healthcare problems. Only in case of emergency or after
referral by the GP, patients visit secondary care profes-
sionals. Moreover, in the Netherlands it is common to
visit one main pharmacy which provides all prescription
medication. As such, the pharmacist has the most accur-
ate and complete medication data.
Randomisation
Randomisation will be performed by a statistician
blinded to characteristics of the practices using a com-
puter generated list of random numbers. The practices
are stratified by practice size (two strata), to ensure
equally sized groups. Before patients are recruited, par-
ticipating practices will be randomly allocated to the
intervention, or control condition. Patients will be allo-
cated to either one of the treatment conditions, based
on the practice where they are listed. Blinding of pa-
tients, GPs and practice nurses to treatment allocation is
not possible due to the nature of the intervention.
Participants
Patients of 65 years and older are eligible if they newly
present with a geriatric giant in general practice use at
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giant is defined as being a first episode if the problem
has not been noted in the patients’ medical file during
the previous 12 months. Patients with geriatric giants
are identified on the basis of the ICPC coded diagnoses
[31] (see Additional file 1) in their electronic medical
record. Chronic use of at least one drug is defined as at
least three prescriptions in the last 12 months in the GP
practice. In The Netherlands, prescriptions are always
for a maximum of three months of treatment.
Screening questionnaire
Together with the invitation for participation in the
study, both intervention and control patients receive a
screening questionnaire. The questionnaire consists of
four parts:
I. Questions on the presence and self-perceived severity
of geriatric giants using visual analogue scales (VAS)
(0–10).The geriatric problems that are evaluated are 1.
Mobility problem; 2. Dizziness; 3. Urinary incontinence;
4. Problems with cognition; 5. Fear of Falling [32]; Also
a question is formulated regarding the number of falls
in the previous 6 months;
II. Questions regarding body weight (kg), length (m)
and pain (VAS 0–10);
III. Actual drug use including OTC drugs;
IV. Questionnaire aimed at the identification of DRPs
from the patient perspective.
Part III and IV of the questionnaire are developed by
the authors of this study and have been shown to have
good agreement with a patient interview during a home
visit [33,34].
Inclusion procedure
For identifying potential participants in the practices a
two-step approach will be applied.
Step 1. Eligible patients will be identified retrospectively
every 8 weeks on the basis of a selected set of ICPC
codes (see Additional file 1), age and chronic use of
at least one drug, through a predefined search
strategy in the GP electronic medical records. Only
patients who consulted the GP with one of these
diagnoses in this time period and who did not
present with this problem to the GP during the
previous 12 months are eligible to participate.
Step 2. Identified potential participants in step 1 will be
invited to fill out the above described screening
questionnaire. If needed, the patient will be offered
support at home to fill out the screening
questionnaire. Patients will be included in the trial if
they indicate to currently have a score of five orhigher on one of the VAS scales of the geriatric
problems or have indicated to have one fall or more
in the previous 6 months. Additionally they have to
indicate that they are willing to participate in the
trial by signing an informed consent form.
Exclusion criteria
Patients are not eligible when they have a diagnosis of
dementia in their medical record. In addition, patients
with a Mini Mental State Examination (MMSE) score of
18 or less will be excluded from the trial, since this is
the cut off for serious cognitive impairment [35,36]. An
MMSE interview is only carried out when patients indi-
cated they needed help to fill out the screening question-
naire. Each 8 weeks, the GPs will receive a list of all
eligible patients and they will exclude patients who re-
ceived a structured CMR in the last 6 months or are ac-
cording to the GP unable to participate (e.g. due to
terminal illness or severe psychiatric problems).
Intervention
Preparatory steps
The research assistant prepares together with the prac-
tice nurse the CMRs for the expert teams (see below).
The required information from the electronic medical
files from the GP practice, the pharmacy and the screen-
ing questionnaire is collected. This information consists
of the actual drug use of the patient including OTC
drugs, drug delivery history, potential DRPs, the medical
problems of the patient, laboratory test results, e.g. renal
function and other measurements such as blood pressure.
Clinical medication review by expert team
An expert team consisting of a GP (not the patient’s GP)
and a pharmacist (not the patient’s pharmacist) will re-
view the medication. The team will carry out a system-
atic assessment aimed at identifying drug related
problems (DRP) experienced by the patient as indicated
in the screening questionnaire and at optimising the
medication of the patient. The medication will be struc-
turally reviewed according to the Dutch Systematic Tool
to Reduce Inappropriate Prescribing (STRIP) method in-
cluding the translated Screening Tool of Older Person’s
Prescriptions (STOPP) and Screening Tool to Alert doc-
tors to Right Treatment (START) criteria [20,29]. A
computer assisted version of the STRIP method, the
STRIP-assistant will be used by the team [37]. First, the
medications are linked to the diseases or symptoms.
Then the following steps will be systematically followed:
1. Undertreatment
2. Effectiveness of treatment
3. Overtreatment
4. Potential adverse events
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6. Dosing problems
7. Other problems, such as user problems, knowledge
or adherence
Finally, the result of this CMR analysis is a pharma-
cotherapeutic treatment plan that will be sent to the pa-
tient’s GP (see Additional file 2) Three expert teams will
be formed for the Opti-Med study.
Implementing the pharmacotherapeutic treatment plan
Patients will be invited for a consultation with the GP in
which both the pharmacotherapeutic treatment plan and
the patient’s perspective as previously assessed with the
screening questionnaire are discussed and definitive
changes in the prescribed medication will be implemented.
Monitoring the medication use
Six months after inclusion a check will be carried out by
the researchers to identify medication changes compared
to the outcome of the CMR (intervention group) and/or
compared to baseline drug use of all participating pa-
tients. The patients’ GPs will receive a signal if new
DRPs are identified. The follow-up of this signal is out-
side the scope of this study.
Training
Expert teams will follow accredited online courses for
medication reviews and pharmacology in elderly and
two medication review workshops. Participating GPs
and practice nurses of the intervention practices will be
instructed how to carry out the study protocol and will
receive a handbook.
Control condition
Eligible patients who are listed in a control practice will
be identified and selected in exactly the same manner as
in the intervention group. They will be asked to give in-
formed consent and to fill in the same questionnaires at
inclusion, baseline, 3 and 6 months. Patients in control
practices receive usual care, which means that no struc-
tured attention will be paid to their medication.
Outcome measures
Measurements by means of patient questionnaires and
proxy assessments will be carried out at baseline, after 3
and 6 months It is expected that some patients will de-
velop either cognitive problems or other difficulties pre-
cluding that they fill out the questionnaires adequately
during the study. Self-assessment in these patients might
therefore be less reliable or become not feasible. Proxy as-
sessment could be a substitute for self-assessment of qual-
ity of life [38]. Therefore, patients will be asked to indicate
two proxies: an informal care giver and a professional caregiver who will fill out a proxy assessment questionnaire of
the patient’s quality of life. Data on morbidity and labora-
tory test results will be collected using medical records in
the GP practices. Characteristics of medication, changes in
medication and adherence to medication will be assessed
using dispensing data from the patient’s pharmacist. All
outcomes will be assessed at patient level.Primary outcome measures
Quality of life (QoL) will be assessed using both the SF-
12 and the EuroQol (EQ-5D-3 L) at baseline, and after 3
and 6 months. The SF-12 covers eight dimensions of
health with two summary scores; physical health (PHS)
and mental health (MHS), and has been validated in
many different countries and populations [39-42]. The
PHS will be used as outcome measure because of its su-
perior responsiveness compared to the MHS [43]. The
EQ-5D-3 L is a generic preference based health status
measure that has been shown to be valid and reliable in
a variety of populations and patient groups [44,45]. The
EQ-5D-3 L will be assessed using information from the
patient and by proxy assessment by an informal carer
and a healthcare professional. The proxies will be asked
to report on QoL from the patients’ perspective [46].
The EQ-5D scores will be used to calculate utilities
using the Dutch tariffs. Quality-adjusted life years
(QALYs) will be calculated using linear interpolation be-
tween time points. Higher QALY scores indicate more
improvement in quality of life [47].
The presence of geriatric giants will be assessed at
baseline with the screening questionnaire. At 3 and
6 months, presence of geriatric giants will be assessed
with the same questions as in the screening question-
naire enabling to assess changes compared to baseline.Secondary outcome measures
The prevalence of DRPs in patients will be determined at
baseline and after 6 months in both groups. The 6 month
questionnaire will be similar to the screening question-
naire omitting questions that only need to be asked at the
beginning of the study. An independent clinical pharma-
cologist and GP will assess the DRPs on the basis of the
screening questionnaire and the pharmacist’s medication
overview using the DOCUMENT checklist [48]. DOCU-
MENT stands for Drug selection, Over- or underdose pre-
scribed, Compliance, Untreated indications, Monitoring,
Education or information, Non-clinical and Toxicity or
adverse reaction and has multiple subcategories.
Research suggests that greater treatment satisfaction is
associated with better compliance [49]. Patient satisfaction
about medication in general will be assessed by the single-
item Medication Satisfaction Questionnaire (MSQ) “Over-
all, how satisfied or dissatisfied are you with your current
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point Likert like scale at baseline, 3 and 6 months [50].
Medication adherence will be measured in two ways;
1. Check for at least one pharmacy delivery in the last
six months for all chronically used medication and
2. Self-reported adherence as questioned in the screening
and follow-up questionnaires at baseline and 6 months.
Self-reported adherence is part of the developed screening
questionnaire.
Costs will be measured from a societal perspective. To
calculate the costs of the intervention, information will
be recorded by the expert team, the GP, the pharmacist
and the practice nurse in terms of time and material
spent on performing the CMR and the monitoring of
the patients. Healthcare costs made by the patient will
be assessed from a societal perspective using an slightly
adapted version of the Dutch Medical Consumption
Questionnaire (iMTA) questionnaire on care consump-
tion, including informal care after 3 months (t = 1) and
after 6 months [51]. Information on prescribed medica-
tion will be derived from the pharmacy administration
information system (PAIS). Lost productivity costs will
not be included since almost all patients will be retired.
Healthcare utilisation will be valued according to guide-
lines for economic evaluation in healthcare in the
Netherlands [52].
Pilot study
Based on the experiences of two small pilot innovation
programs, the intervention program was developed ([53]
and unpublished results Elders and Bleeker 2009). An
Opti-Med pilot study was conducted in two intervention
and two control practices for eight weeks including 10 pa-
tients. An evaluation was conducted to test the logistics,
baseline measurements, questionnaires, and the feasibility
and functioning of the expert team of the study. The pilot
study resulted in minor changes in the questionnaire in-
structions, improvements in logistics and communication
with the GP practices.
Process analysis
The process evaluation involves assessing the extent to
which the intervention is performed according to the
protocol of the study, the time that is spent by the pro-
fessionals to perform the activities of the protocol, the
nature of the recommendations made to the patients by
the GP, compliance with these recommendations, the
judgment of the GPs, pharmacists and practice nurses
about the intervention program. Data on these topics
are collected using structured registration forms during
the intervention. In addition, semi-structured interviews
will be held with the participating practice nurses, GPs
and members of the expert teams at the end of the inter-
vention period in order to record their experiences andopinions on the CMR program. The presence and influ-
ence of possible contamination in both intervention and
control practices will also be assessed by interviewing
GPs or practice nurses at the end of the trial on their
opinions to what degree structured attention to medica-
tion was an issue during the study period in general or
with regard to specific patients.
Sample size
The size of the study groups is based on the difference
in change over 6 months between the intervention and
control group of the EQ-5D VAS score (score range 0–
100). A difference of 7.4 in the EQ-5D VAS is consid-
ered as a clinically relevant difference [54]. The average
score among persons with osteoarthritis, a comparable
group, is 64.8 (standard deviation 26.5). To establish a
difference of 7.4 points as statistically significant with
alpha = 0.05 and beta = 0.20, a group size of 225 is suffi-
cient, taking the clustered design into account. To adjust
for loss to follow up of 10% we will include 500 patients.
Statistical analyses
Descriptive statistics will be used to describe the study
population. Dropout and loss to follow up will be described.
Effect analyses will be performed according to both
‘intention to treat’ and per protocol principles. Differences
between intervention and usual care patients on the out-
come measures will be compared between the intervention
and control group by both univariate and multivariate tech-
niques. Multilevel linear and logistic regression analyses will
be performed to study differences between the intervention
and the control patients. Multilevel analysis is needed in
order to take clustering on the GP level and repeated mea-
surements in one patient into account. We will adjust for
possible confounders, such as gender, age, education level,
number of medications and multi-morbidity.
Possible future subgroup analyses will be exploratory,
due to lack of power.
Economic evaluation
For the economic evaluation, missing cost and effect data
will be imputed using multiple imputation according to
the Multivariate Imputation by Chained Equations (MICE)
algorithm developed by van Buuren using predictive mean
matching and fully conditional specification [55]. The
number of imputed datasets will be increased until the
fraction of missing information is below 5% [56]. The im-
puted datasets will be analysed separately as described
below and subsequently pooled using Rubin’s rules.
The effect measures that will be taken into account in the
cost-effectiveness are QALYs, and changes in the VAS
scores of the geriatric giant symptoms. For effects and
costs, linear multilevel regression models will be estimated.
Clustering at the level of GP practice will be included in
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tios (ICERs) will be calculated by dividing the difference in
mean total costs between the treatment and control
groups by the difference in mean effects between the
groups. Costs generally have a highly skewed distribution;
therefore, bootstrapping with 5,000 replications will be
used to estimate bias-corrected and accelerated confi-
dence intervals around cost differences [57]. To account
for the clustering of data, bootstrap replications will be
stratified for practice [58]. The uncertainty surrounding
the ICERs which will be graphically presented on cost-
effectiveness planes. Cost-effectiveness acceptability curves
and net monetary benefits will also be calculated. Cost-
effectiveness acceptability curves show the probability that
the medication review programme is cost-effective in
comparison with usual care for a range of different ceiling
ratios thereby showing decision uncertainty.
Discussion
This study is expected to add evidence on the effectiveness
and cost-effectiveness of an optimally facilitated, prepared
and structured CMR in comparison with usual care in
older patients presenting with a geriatric giant to their GP.
Geriatric giants are highly prevalent among older people
and represent a major cause of impaired quality of life.
Optimising the patient’s medication in addition to treating
these geriatric problems or delaying their worsening by
treatment, is expected to have a positive additional impact
on the patient’s perceived health. Moreover, optimising
drug use will also improve the effectiveness of drug treat-
ment, prevent adverse drug reactions and potentially
harmful drug interactions, and consequently hospital ad-
missions or even death.
For healthcare professionals, handling DRPs in older
people is a challenge. The burden of aging on the health-
care sector, care efficiency is an important issue.
The streamlining of the process, the experienced expert
teams and minimising the contact moments with the pa-
tients due to the written questionnaire as proposed in this
study increases the feasibility that CMRs can be imple-
mented successfully in usual care. In practice, after this
study, expert teams could be implemented in a GP cooper-
ation or another regional care settings in which pharma-
cists and GPs should be trained and form expert groups.
The strength of this study is that it will be conducted
in daily clinical practice and will resemble daily clinical
practice as much as possible. This improves the possibil-
ities to implement CMRs in the primary care setting.
The most important innovations compared to previous
programs are:
1. The CMR will not focus primarily on polypharmacy
patients, instead the selection of older patients is
based on episodes related to a geriatric giant;2. The CMR is prepared by a trained expert team
consisting of an external GP and an external
pharmacist who formulate a pharmacotherapeutic
treatment plan for the patient’s GP;
3. The coordination of the CMR at the primary care
level is performed by a case manager, usually the
practice nurse or assistant;
4. The number of contacts with the patient is reduced
by assessing the patient’s perspective by a written
questionnaire instead of a home visit.
Quality of life is the primary outcome measure. This
may not be sensitive enough to capture the changes in-
duced by the intervention. However, we have chosen to
use generic health measures as primary outcome mea-
sures because we include patients in this study that
might have a variety of geriatric symptoms with a het-
erogeneous treatment effect. Also we think that in this
population quality of life is the most important outcome.
In addition, the study is not blinded and there is a possi-
bility of contamination between the intervention and con-
trol group. We counter possible contamination between
treatments groups by using a cluster randomised con-
trolled design. That way, caregivers cannot unintentionally
apply aspects of the Opti-Med study into their usual care
for patients. Patients in the control condition also fill out
the screening questionnaire on actual drug use and medi-
cation related problems, this is needed for the study, but
could underestimate the effectiveness of Opti-Med by in-
creasing awareness of possible drug related problems in
these control participants. Furthermore, we suppose that
current activities on older people care and possible future
pharmacist’s polypharmacy projects are minimally inter-
fering with the study. This assumption about possible con-
tamination will be checked during the process analysis.
Implementation of structured CMR and monitoring
will raise the awareness about the importance of opti-
mising medication use in general, and especially in older
patients among healthcare professionals. In this study,
we will evaluate a form of a structured CMR that can
easily be implemented in a GP cooperation or care
group. If the CMR is shown (cost-) effective and feasible
it could also be extrapolated to other groups of patients
in the future in whom inappropriate medication use is
suspected as well. If proven cost-effective, this will sup-
port the nationwide implementation of this structured
approach. The first results of the study will be expected
at the end of 2015.Additional files
Additional file 1: ICPC codes for the selection of patients with
geriatric giants in the Opti-Med study.
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Opti-Med.
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